doi: 10.1016/0006-8993(81)90171-2.
Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease
- PMID: 6164436
- DOI: 10.1016/0006-8993(81)90171-2
Item in Clipboard
Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease
Brain Res.
.
Abstract
Substance P (SP) levels were determined by radioimmunoassay (RIA) in several regions of post-mortem brain of controls and Huntington's disease (HD) patients. In controls, highest SP levels were found in basal ganglia, substantia nigra and hypothalamus. Nigral pars reticulata contained 3--4-fold higher levels than pars compacta. In HD, SP levels were reduced in all basal ganglia and substantia nigra. The reductions ranged from 48% in caudate nucleus to over 90% in nigral pars reticulata. There were no changes in SP levels in HD frontal cortex, thalamus or hypothalamus.
Similar articles
-
Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.Brain Res. 1983 Dec 19;289(1-2):11-26. doi: 10.1016/0006-8993(83)90003-3. Brain Res. 1983. PMID: 6198034
-
Substance P appears reduced in Huntington's disease: immunocytochemical findings in substantia nigra and substantia gelatinosa.J Submicrosc Cytol. 1983 Apr;15(2):569-82. J Submicrosc Cytol. 1983. PMID: 6190005
-
Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.Neuroscience. 1988 May;25(2):419-38. doi: 10.1016/0306-4522(88)90249-7. Neuroscience. 1988. PMID: 2456487
-
Substance P and substance P receptor histochemistry in human neurodegenerative diseases.Regul Pept. 1993 Jul 2;46(1-2):174-85. doi: 10.1016/0167-0115(93)90028-7. Regul Pept. 1993. PMID: 7692486 Review.
-
The relationships of aging changes in the basal ganglia to manifestations of Huntington's chorea.Ann Neurol. 1980 May;7(5):406-11. doi: 10.1002/ana.410070503. Ann Neurol. 1980. PMID: 6446874 Review. No abstract available.
Cited by
-
A local circuit model of learned striatal and dopamine cell responses under probabilistic schedules of reward.J Neurosci. 2008 Oct 1;28(40):10062-74. doi: 10.1523/JNEUROSCI.0259-08.2008. J Neurosci. 2008. PMID: 18829964 Free PMC article.
-
Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease.J Neurosci. 1996 Aug 15;16(16):5168-81. doi: 10.1523/JNEUROSCI.16-16-05168.1996. J Neurosci. 1996. PMID: 8756445 Free PMC article.
-
Differential loss of striatal projection neurons in Huntington disease.Proc Natl Acad Sci U S A. 1988 Aug;85(15):5733-7. doi: 10.1073/pnas.85.15.5733. Proc Natl Acad Sci U S A. 1988. PMID: 2456581 Free PMC article.
-
Imaging in cell-based therapy for neurodegenerative diseases.Eur J Nucl Med Mol Imaging. 2005 Dec;32 Suppl 2:S417-34. doi: 10.1007/s00259-005-1909-6. Eur J Nucl Med Mol Imaging. 2005. PMID: 16267643 Review.
-
Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.Mol Cell Proteomics. 2009 May;8(5):1094-104. doi: 10.1074/mcp.M800454-MCP200. Epub 2009 Jan 8. Mol Cell Proteomics. 2009. PMID: 19131325 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
etc
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
